Developer docs
API playgroundTry for free, no card

Search company profiles

Brains Bioceutical

Full company profile

uuid0002cp3

Namestring
Brains Bioceutical
Legal namestring
Brains Bioceutical Corp.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Brains Bioceutical Corp. is a Vancouver-headquartered, privately held cannabinoid life sciences company operating through its wholly-owned UK subsidiary BSPG Laboratories Ltd. The company manufactures pharmaceutical-grade cannabinoid active pharmaceutical ingredients (APIs) — including CBD, D9-THC (in solid crystalline form), D8-THC, CBN, and CBG — at a 25,000 sq ft EU-GMP certified facility in Sandwich, Kent, originally established as a Pfizer Discovery Park site. Brains Bio produces 500+ commercial GMP batches annually with zero quality failures, holds 36-month stability data, sub-0.15% impurity profiles, and an industry-low 0.000006% THC detection threshold, supplying APIs into 30+ clinical trials across epilepsy, opioid addiction, anxiety, insomnia, and inflammation indications.

The company monetizes through four interlinked revenue streams: (1) pharmaceutical API supply under long-term contracted agreements extending through 2030, (2) a pharmaceutical development division pursuing licensing and co-development partnerships (e.g., DSM-Firmenich exclusive global alliance, Effcon for glaucoma under FDA Special Protocol Assessment, Prati for refractory epilepsy in Brazil), (3) a nutraceuticals division operating a three-tier brand architecture (Brains Pure at Harrods, Vitabiotics x Brains in pharmacy chains across 100+ countries, Vitality CBD on Amazon and in Tesco/ASDA/Bootes/Holland & Barrett), and (4) an animal health division targeting companion animal therapeutics. Regulatory positioning is unusually deep: EU-GMP, EudraGMDP, MHRA API registration, US Drug Master File, EU ASMF, ANVISA, TGA, UK Novel Food validation (first for naturally sourced CBD), NSF/ANSI 173 certification, NSF Certified for Sport, and an in-progress EDQM CEP application.

Go-to-market combines enterprise field sales to multinational pharmaceutical companies with a multi-tiered channel partner strategy across UK retail pharmacy, premium department stores, Amazon e-commerce, and regional distributors across six continents. Distribution partners include Cronos Australia, a major Brazilian pharmaceutical manufacturer, and Vitabiotics (UK's #1 vitamin company). The company is cash-flow positive, supported by US$62M of cumulative disclosed funding, and led by an executive team combining Big Pharma veterans from Biogen, GlaxoSmithKline, and GW Pharma with cannabis-industry specialists.

Short descriptiontext

Brains Bioceutical is a Vancouver-based cannabinoid life sciences company that manufactures EU-GMP certified pharmaceutical-grade cannabinoid APIs (CBD, THC, CBN, CBG) at its UK facility, supplying pharmaceutical companies, clinical researchers, nutraceutical brands, and veterinary markets across six continents.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical cannabinoid APIs, EU-GMP manufacturing, cannabinoid nutraceuticals, veterinary cannabinoid therapeutics, natural plant-based CBD
Industry3 codes
PRIMARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAGAE
Process Development & Tech Transfer (Upstream/Downstream/MSAT)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Cannabinoid APIs
Social media profiles3 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical API Supply
TypeLicensing Royalties
Description

Supply of EU-GMP certified cannabinoid APIs (CBD, THC, CBN, CBG) to pharmaceutical companies for clinical trials and commercial applications. Revenue secured through long-term supply agreements and contracted revenue pipeline through 2030.

brainsbioceutical.com
2Nutraceutical Products
TypeOne Time License
Description

Three-tier brand architecture: Brains Pure (premium Harrods placement), Vitabiotics x Brains (pharmacy chains), Vitality CBD (Amazon and major retailers). Co-branded and white-label products through Vitabiotics partnership.

brainsbioceutical.com
3Pharmaceutical Licensing
TypeLicensing Royalties
Description

High-margin licensing revenue through pharmaceutical partnerships and direct commercialization of proprietary formulations. Includes CEP certification enabling streamlined regulatory processes for pharmaceutical manufacturers globally.

brainsbioceutical.com
4Contract Manufacturing
TypeProfessional Services
Description

Custom formulation development and finished product manufacturing for pharmaceutical and nutraceutical partners. End-to-end solutions from API to finished dosage forms.

brainsbioceutical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Technology or R&D, Operations, Supply Chain, Personnel, Infrastructure, Marketing or Sales, Others
Pricing details1 tier
1B2B pharmaceutical API supply contracts
ModelTransaction based/ take rateBilling cadenceMulti-year contract
Notes

Contract pricing based on volume, purity specifications, and regulatory requirements. Long-term supply agreements with contracted revenue through 2030.

brainsbioceutical.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Brains Pure
Description

Premium CBD brand positioned at Harrods for high-net-worth wellness consumers.

brainsbioceutical.com
+4 more records
Core offering1 text field

Brains Bioceutical is a cannabinoid life sciences company that manufactures EU-GMP certified pharmaceutical-grade active pharmaceutical ingredients (APIs) including CBD, D9-THC, D8-THC, CBN, and CBG at its UK facility. The company leverages these APIs across four pillars: pharmaceutical APIs for drug developers, therapeutic development programs, branded nutraceutical products, and veterinary applications. Revenue is anchored by multi-year B2B supply contracts with pharmaceutical, nutraceutical, and animal health companies globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 500+ commercial GMP batches with zero quality failures
+6 more records
Product overview1 text field

Brains Bioceutical operates as a diversified cannabinoid life sciences company organized into four strategic pillars: Brains API (pharmaceutical-grade cannabinoid APIs), Pharmaceuticals (therapeutic development programs), Nutraceuticals (wellness products), and Animal Health (veterinary applications). The Brains API division serves as the foundational engine, producing EU-GMP certified APIs including CBD, D9-THC, D8-THC, CBN, and CBG that power all other segments. The Pharmaceuticals division leverages these APIs for clinical programs targeting opioid use disorder, refractory epilepsy, glaucoma, and insomnia. The Nutraceuticals division converts APIs into consumer products through owned brands (Brains Pure, Vitality CBD, Jorja's Botanicals) and co-branded offerings with Vitabiotics. The Animal Health division applies the same EU-GMP platform to veterinary applications. The company also operates BrainsAI, an AI-powered precision medicine ecosystem for CNS disorder drug discovery, and BSPG Laboratories, its wholly-owned UK manufacturing subsidiary.

Product and service13 records
1EU GMP CBD API
CategoryActive Pharmaceutical Ingredient
Description

Pharmaceutical-grade Cannabidiol (CBD) active pharmaceutical ingredient manufactured at EU-GMP certified facilities with 99.7% purity and ultra-low THC content. Sold to pharmaceutical companies, contract manufacturers, and researchers for clinical trials and finished dosage forms.

2D9-THC API (Solid Crystalline Form)
CategoryActive Pharmaceutical Ingredient
Description

Delta-9-Tetrahydrocannabinol API in solid crystalline form—a world's first breakthrough enabling precise dosing and improved stability compared to liquid THC formulations. Supplied to pharmaceutical developers and researchers for cannabinoid-based drug development.

3CBN API
CategoryActive Pharmaceutical Ingredient
Description

Cannabinol API available as EU-GMP certified active pharmaceutical ingredient for emerging therapeutic applications. Supplied to pharmaceutical developers for novel drug development programs.

4CBG API
CategoryActive Pharmaceutical Ingredient
Description

Cannabigerol API in final validation as part of the company's pharmaceutical-grade cannabinoid portfolio, with early-mover advantage in emerging therapeutics. Supplied to pharmaceutical and nutraceutical developers.

5D8-THC API
CategoryActive Pharmaceutical Ingredient
Description

Delta-8-Tetrahydrocannabinol API for medical applications requiring controlled substance capabilities. Supplied to pharmaceutical companies and researchers.

6Opioid Use Disorder Program
CategoryPharmaceutical Therapeutics
Description

Cannabinoid therapeutic development program for opioid use disorder under NIH-funded Phase 3 trial, leveraging proprietary oral CBD formulation. Targets the >$450M peak revenue opportunity in the $8.4B opioid use disorder market.

7Refractory Epilepsy Program
CategoryPharmaceutical Therapeutics
Description

Cannabinoid therapeutic development program for refractory epilepsy with Phase III study under ANVISA review in Brazil. Positioned to become the first globally market-authorized CBD pharmaceutical through partnership with Prati.

8Brains Pure
CategoryNutraceutical Consumer Brand
Description

Premium CBD consumer brand positioned at Harrods targeting high-net-worth wellness consumers seeking pharmaceutical-grade quality and verified purity.

9Vitality CBD
CategoryNutraceutical Consumer Brand
Description

Mass market CBD brand distributed through Amazon and major UK retailers (Holland & Barrett, Boots, Tesco, ASDA) targeting price-conscious wellness consumers.

10Vitabiotics x Brains
CategoryNutraceutical Co-Branded Product
Description

Co-branded CBD nutraceutical products with Vitabiotics (UK's #1 vitamin company), distributed across 100+ countries through pharmacy chains and retailers.

11PURUS Range
CategoryPharmaceutical Product Line
Description

Combination CBD:THC products in various ratios (PURUS SA, PURUS 20, PURUS 50) for personalized cannabinoid medication and therapeutic applications.

12Animal Health Cannabinoid APIs
CategoryVeterinary Pharmaceuticals
Description

Veterinary cannabinoid APIs and products targeting companion animal wellness and prescription therapeutics across multiple species, including canine osteoarthritis, epilepsy, anxiety, and feline stress conditions.

13Brains Bio API Division
CategoryCannabinoid API Supply
Description

Core API division supplying EU-GMP certified cannabinoid APIs (CBD, D9-THC, D8-THC, CBN, CBG) to pharmaceutical, nutraceutical, and animal health markets worldwide through contracted revenue agreements.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-09
Description

Clinical trial partnership for PK study using Brains Bio's oral CBD formulation as foundation for potential opioid addiction studies. Mount Sinai's multidisciplinary research team investigating neurobiology of addiction disorders.

2Tamar Technologies
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Strategic partnership providing access to biopharmaceutical technologies, cannabinoids and phytochemical products, and delivery mechanisms. Investment and partnership opened doors for specialty pharmaceutical advancements and global market expansion.

brainsbioceutical.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-07-28
Description

Supply agreement for CBD products distribution in Australia. Cronos Australia (joint venture between Cronos Group and NewSouthern Capital) to distribute Brains Bio products under the 'Adaya' product line following TGA approval.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-06-17
Description

Letter of Intent for Tamar to distribute Brains Bio's naturally sourced CBD API to Ramot and/or Yissum for use in InnoCan's CBD research projects including exosome-based technology and liposome delivery platforms.

5Brazilian Pharmaceutical Partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-04-24
Description

Partnership with leading Brazilian pharmaceutical company (producing 11.5 billion therapeutic doses annually with 4,200+ employees) for supply of EU-GMP CBD API for Brazil's first registered medical cannabis product under ANVISA regulations.

brainsbioceutical.com
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Exclusive multi-year agreement with UK's #1 vitamin company (27% market share) for co-branded and white-label CBD products. Partnership provides immediate access to Vitabiotics' distribution across 100+ countries and established credibility in the nutraceutical market.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Exclusive global partnership for joint commercialization and innovation platform for early-stage cannabinoid drug development. DSM-Firmenich provides formulation expertise, global regulatory specialists, and preclinical/clinical study capabilities. Combined expertise aims to realize potential of CBD-based formulations.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Research partnership with scientific partners at King's College London investigating CBD effects on mental health conditions including anxiety, depression, PTSD, and COVID-19 clinical study proposals.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

State-of-the-art interdisciplinary athletics training facility exploring, experimenting, and evaluating power of CBD API in elite athletes. Partnership combines sports medicine expertise with pharmaceutical-grade CBD research.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Clinical trial supply partnership for CBD research studies in Australia at the Melbourne Brain Centre.

11Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE)
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Clinical research partnership with Australia's leading cannabinoid research center for CBD clinical trials.

brainsbioceutical.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnership for regulatory filing in Brazil for refractory epilepsy treatment using CBD API. Prati is advancing toward first globally market-authorized CBD pharmaceutical.

13Effcon (USA)
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Partnership for extended-release glaucoma treatment advancing under FDA Special Protocol Assessment with Effcon.

brainsbioceutical.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian GMP-certified cannabinoid API manufacturer competing for similar pharmaceutical and nutraceutical customers. Most direct competitor in the cannabinoid API supply business, though MediPharm's regulatory certifications and scale are narrower than Brains' EU-GMP footprint.

TypeBroad incumbent
Description

Canadian cannabis operator with pharmaceutical ambitions; Cronos Australia (a Cronos-NewSouthern JV) is an actual Brains Bio distribution partner. Competes with Brains on certain API/finished product lines and is a relevant comparable for global cannabis-pharma strategy.

3Acreo Health Sciences
TypeEmerging player
Description

EU-based pharmaceutical-grade medical cannabis producer serving wholesalers, pharmacies, and pharma customers across Europe. Comparable in focusing on EU-GMP pharmaceutical-grade supply, though smaller scale than Brains' 12.6-ton annual capacity.

TypeBroad incumbent
Description

Large Canadian cannabis producer with EU-GMP facilities supplying medical and consumer markets in Europe. Comparable scale of operations and regulatory positioning, though Aurora's product mix is broader and more cultivation-centric than Brains' pure API manufacturer model.

TypeBroad incumbent
Description

Major Canadian cannabis operator pursuing pharmaceutical-grade cannabinoid products and global distribution. Broader and more consumer-facing than Brains but overlaps on pharmaceutical-grade CBD positioning and clinical research investments.

6Botanix Pharmaceuticals
TypeEmerging player
Description

Clinical-stage cannabinoid therapeutics developer focused on dermatology and antimicrobial applications. Similar pharmaceutical-outlook strategy to Brains' pharma division but narrower indication focus and earlier pipeline stage.

TypeEmerging player
Description

Israeli-Canadian pharmaceutical company developing cannabinoid-loaded exosome and liposome delivery platforms. Connected to Brains via a Tamar Technologies distribution LOI; comparable in pharmaceutical-grade cannabinoid development though at earlier commercialization stage.

TypeDirect peer
Description

Owns GW Pharmaceuticals, the pioneer of pharmaceutical-grade cannabinoid drug development (Epidiolex). Most direct comparison point for Brains' strategy of converting naturally-sourced cannabinoids into approved, regulated pharmaceutical products — though Jazz operates further downstream in branded drug commercialization.

9Tilray Brands
TypeBroad incumbent
Description

Large diversified cannabis operator with pharmaceutical division (Tilray Medical) distributing cannabinoid APIs and finished products globally. Competes with Brains on the nutraceutical/consumer side and overlaps on API supply to pharma, but Tilray's vertically integrated cultivation-and-retail model differs from Brains' pure-play API focus.

TypeEmerging player
Description

Clinical-stage pharmaceutical company developing cannabinoid-based therapies for inflammatory heart disease. Comparable in pursuing FDA-style regulated pathways with pharmaceutical-grade CBD formulations, though a single-indication focus rather than platform play.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance21 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Brains Bioceutical

Pharmaceutical Cannabinoid APIsbrainsbioceutical.com

Brains Bioceutical is a Vancouver-based cannabinoid life sciences company that manufactures EU-GMP certified pharmaceutical-grade cannabinoid APIs (CBD, THC, CBN, CBG) at its UK facility, supplying pharmaceutical companies, clinical researchers, nutraceutical brands, and veterinary markets across six continents.

What Brains Bioceutical does

Brains Bioceutical Corp. is a Vancouver-headquartered, privately held cannabinoid life sciences company operating through its wholly-owned UK subsidiary BSPG Laboratories Ltd. The company manufactures pharmaceutical-grade cannabinoid active pharmaceutical ingredients (APIs) — including CBD, D9-THC (in solid crystalline form), D8-THC, CBN, and CBG — at a 25,000 sq ft EU-GMP certified facility in Sandwich, Kent, originally established as a Pfizer Discovery Park site. Brains Bio produces 500+ commercial GMP batches annually with zero quality failures, holds 36-month stability data, sub-0.15% impurity profiles, and an industry-low 0.000006% THC detection threshold, supplying APIs into 30+ clinical trials across epilepsy, opioid addiction, anxiety, insomnia, and inflammation indications.

The company monetizes through four interlinked revenue streams: (1) pharmaceutical API supply under long-term contracted agreements extending through 2030, (2) a pharmaceutical development division pursuing licensing and co-development partnerships (e.g., DSM-Firmenich exclusive global alliance, Effcon for glaucoma under FDA Special Protocol Assessment, Prati for refractory epilepsy in Brazil), (3) a nutraceuticals division operating a three-tier brand architecture (Brains Pure at Harrods, Vitabiotics x Brains in pharmacy chains across 100+ countries, Vitality CBD on Amazon and in Tesco/ASDA/Bootes/Holland & Barrett), and (4) an animal health division targeting companion animal therapeutics. Regulatory positioning is unusually deep: EU-GMP, EudraGMDP, MHRA API registration, US Drug Master File, EU ASMF, ANVISA, TGA, UK Novel Food validation (first for naturally sourced CBD), NSF/ANSI 173 certification, NSF Certified for Sport, and an in-progress EDQM CEP application.

Go-to-market combines enterprise field sales to multinational pharmaceutical companies with a multi-tiered channel partner strategy across UK retail pharmacy, premium department stores, Amazon e-commerce, and regional distributors across six continents. Distribution partners include Cronos Australia, a major Brazilian pharmaceutical manufacturer, and Vitabiotics (UK's #1 vitamin company). The company is cash-flow positive, supported by US$62M of cumulative disclosed funding, and led by an executive team combining Big Pharma veterans from Biogen, GlaxoSmithKline, and GW Pharma with cannabis-industry specialists.

Brains Bioceutical firmographics

Firmographics
Name
Brains Bioceutical
Legal name
Brains Bioceutical Corp.
Website
https://brainsbioceutical.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Brains Bioceutical is a Vancouver-based cannabinoid life sciences company that manufactures EU-GMP certified pharmaceutical-grade cannabinoid APIs (CBD, THC, CBN, CBG) at its UK facility, supplying pharmaceutical companies, clinical researchers, nutraceutical brands, and veterinary markets across six continents.
Ownership category
akta.pro rank

Brains Bioceutical industry classification

Industry
Product category
Pharmaceutical Cannabinoid APIs
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAGAE
Process Development & Tech Transfer (Upstream/Downstream/MSAT)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Pharmaceutical cannabinoid APIs
  • EU-GMP manufacturing
  • Cannabinoid nutraceuticals
  • Veterinary cannabinoid therapeutics
  • Natural plant-based CBD

Where Brains Bioceutical is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Brains Bioceutical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Supply Chain, Personnel, Infrastructure, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical API Supply: Supply of EU-GMP certified cannabinoid APIs (CBD, THC, CBN, CBG) to pharmaceutical companies for clinical trials and commercial applications. Revenue secured through long-term supply agreements and contracted revenue pipeline through 2030.
  2. Nutraceutical Products: Three-tier brand architecture: Brains Pure (premium Harrods placement), Vitabiotics x Brains (pharmacy chains), Vitality CBD (Amazon and major retailers). Co-branded and white-label products through Vitabiotics partnership.
  3. Pharmaceutical Licensing: High-margin licensing revenue through pharmaceutical partnerships and direct commercialization of proprietary formulations. Includes CEP certification enabling streamlined regulatory processes for pharmaceutical manufacturers globally.
  4. Contract Manufacturing: Custom formulation development and finished product manufacturing for pharmaceutical and nutraceutical partners. End-to-end solutions from API to finished dosage forms.

Pricing tiers

ModelBillingPrice
Transaction based/ take rateMulti-year contractB2B pharmaceutical API supply contracts

Go-to-market motion4 records

Distribution channels5 records

Marketing channels5 records

Brains Bioceutical product offering

Product offering

Core offering

Brains Bioceutical is a cannabinoid life sciences company that manufactures EU-GMP certified pharmaceutical-grade active pharmaceutical ingredients (APIs) including CBD, D9-THC, D8-THC, CBN, and CBG at its UK facility. The company leverages these APIs across four pillars: pharmaceutical APIs for drug developers, therapeutic development programs, branded nutraceutical products, and veterinary applications. Revenue is anchored by multi-year B2B supply contracts with pharmaceutical, nutraceutical, and animal health companies globally.

Product overview

Brains Bioceutical operates as a diversified cannabinoid life sciences company organized into four strategic pillars: Brains API (pharmaceutical-grade cannabinoid APIs), Pharmaceuticals (therapeutic development programs), Nutraceuticals (wellness products), and Animal Health (veterinary applications). The Brains API division serves as the foundational engine, producing EU-GMP certified APIs including CBD, D9-THC, D8-THC, CBN, and CBG that power all other segments. The Pharmaceuticals division leverages these APIs for clinical programs targeting opioid use disorder, refractory epilepsy, glaucoma, and insomnia. The Nutraceuticals division converts APIs into consumer products through owned brands (Brains Pure, Vitality CBD, Jorja's Botanicals) and co-branded offerings with Vitabiotics. The Animal Health division applies the same EU-GMP platform to veterinary applications. The company also operates BrainsAI, an AI-powered precision medicine ecosystem for CNS disorder drug discovery, and BSPG Laboratories, its wholly-owned UK manufacturing subsidiary.

Differentiator

Problem solved

Functional benefit

Brands

  • Brains Pure: Premium CBD brand positioned at Harrods for high-net-worth wellness consumers.
  • Brains Inside
  • Jorja's Botanicals
  • PURUS
  • BSPG Laboratories

Products and services

  • EU GMP CBD API Pharmaceutical-grade Cannabidiol (CBD) active pharmaceutical ingredient manufactured at EU-GMP certified facilities with 99.7% purity and ultra-low THC content. Sold to pharmaceutical companies, contract manufacturers, and researchers for clinical trials and finished dosage forms.
  • D9-THC API (Solid Crystalline Form) Delta-9-Tetrahydrocannabinol API in solid crystalline form—a world's first breakthrough enabling precise dosing and improved stability compared to liquid THC formulations. Supplied to pharmaceutical developers and researchers for cannabinoid-based drug development.
  • CBN API Cannabinol API available as EU-GMP certified active pharmaceutical ingredient for emerging therapeutic applications. Supplied to pharmaceutical developers for novel drug development programs.
  • CBG API Cannabigerol API in final validation as part of the company's pharmaceutical-grade cannabinoid portfolio, with early-mover advantage in emerging therapeutics. Supplied to pharmaceutical and nutraceutical developers.
  • D8-THC API Delta-8-Tetrahydrocannabinol API for medical applications requiring controlled substance capabilities. Supplied to pharmaceutical companies and researchers.
  • Opioid Use Disorder Program Cannabinoid therapeutic development program for opioid use disorder under NIH-funded Phase 3 trial, leveraging proprietary oral CBD formulation. Targets the >$450M peak revenue opportunity in the $8.4B opioid use disorder market.
  • Refractory Epilepsy Program Cannabinoid therapeutic development program for refractory epilepsy with Phase III study under ANVISA review in Brazil. Positioned to become the first globally market-authorized CBD pharmaceutical through partnership with Prati.
  • Brains Pure Premium CBD consumer brand positioned at Harrods targeting high-net-worth wellness consumers seeking pharmaceutical-grade quality and verified purity.
  • Vitality CBD Mass market CBD brand distributed through Amazon and major UK retailers (Holland & Barrett, Boots, Tesco, ASDA) targeting price-conscious wellness consumers.
  • Vitabiotics x Brains Co-branded CBD nutraceutical products with Vitabiotics (UK's #1 vitamin company), distributed across 100+ countries through pharmacy chains and retailers.
  • PURUS Range Combination CBD:THC products in various ratios (PURUS SA, PURUS 20, PURUS 50) for personalized cannabinoid medication and therapeutic applications.
  • Animal Health Cannabinoid APIs Veterinary cannabinoid APIs and products targeting companion animal wellness and prescription therapeutics across multiple species, including canine osteoarthritis, epilepsy, anxiety, and feline stress conditions.
  • Brains Bio API Division Core API division supplying EU-GMP certified cannabinoid APIs (CBD, D9-THC, D8-THC, CBN, CBG) to pharmaceutical, nutraceutical, and animal health markets worldwide through contracted revenue agreements.

Quantifiable outcome

  • 500+ commercial GMP batches with zero quality failures
  • +6 more outcomes

Companies that use Brains Bioceutical

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Brains Bioceutical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Brains Bioceutical partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core, strategic, minor and flagship.

  • Icahn School of Medicine at Mount SinaicoreStrategic or Co-development Partner · 9 February 2022Clinical trial partnership for PK study using Brains Bio's oral CBD formulation as foundation for potential opioid addiction studies. Mount Sinai's multidisciplinary research team investigating neurobiology of addiction disorders.
  • Tamar TechnologiesstrategicStrategic or Co-development Partner · 1 January 2021Strategic partnership providing access to biopharmaceutical technologies, cannabinoids and phytochemical products, and delivery mechanisms. Investment and partnership opened doors for specialty pharmaceutical advancements and global market expansion.
  • Cronos AustraliacoreChannel Partner/ Reseller/ Distributor · 28 July 2020Supply agreement for CBD products distribution in Australia. Cronos Australia (joint venture between Cronos Group and NewSouthern Capital) to distribute Brains Bio products under the 'Adaya' product line following TGA approval.
  • InnoCan PharmaminorChannel Partner/ Reseller/ Distributor · 17 June 2020Letter of Intent for Tamar to distribute Brains Bio's naturally sourced CBD API to Ramot and/or Yissum for use in InnoCan's CBD research projects including exosome-based technology and liposome delivery platforms.
  • Brazilian Pharmaceutical PartnercoreChannel Partner/ Reseller/ Distributor · 24 April 2020Partnership with leading Brazilian pharmaceutical company (producing 11.5 billion therapeutic doses annually with 4,200+ employees) for supply of EU-GMP CBD API for Brazil's first registered medical cannabis product under ANVISA regulations.
  • VitabioticsflagshipStrategic or Co-development PartnerExclusive multi-year agreement with UK's #1 vitamin company (27% market share) for co-branded and white-label CBD products. Partnership provides immediate access to Vitabiotics' distribution across 100+ countries and established credibility in the nutraceutical market.
  • DSM-FirmenichflagshipStrategic or Co-development PartnerExclusive global partnership for joint commercialization and innovation platform for early-stage cannabinoid drug development. DSM-Firmenich provides formulation expertise, global regulatory specialists, and preclinical/clinical study capabilities. Combined expertise aims to realize potential of CBD-based formulations.
  • King's College LondonstrategicStrategic or Co-development PartnerResearch partnership with scientific partners at King's College London investigating CBD effects on mental health conditions including anxiety, depression, PTSD, and COVID-19 clinical study proposals.
  • ALTIS/Brains Bioceutical Living LabstrategicStrategic or Co-development PartnerState-of-the-art interdisciplinary athletics training facility exploring, experimenting, and evaluating power of CBD API in elite athletes. Partnership combines sports medicine expertise with pharmaceutical-grade CBD research.
  • Melbourne Brain Centre at Royal Melbourne HospitalstrategicStrategic or Co-development PartnerClinical trial supply partnership for CBD research studies in Australia at the Melbourne Brain Centre.
  • Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE)strategicStrategic or Co-development PartnerClinical research partnership with Australia's leading cannabinoid research center for CBD clinical trials.
  • Prati (Brazil)coreChannel Partner/ Reseller/ DistributorPartnership for regulatory filing in Brazil for refractory epilepsy treatment using CBD API. Prati is advancing toward first globally market-authorized CBD pharmaceutical.
  • Effcon (USA)strategicStrategic or Co-development PartnerPartnership for extended-release glaucoma treatment advancing under FDA Special Protocol Assessment with Effcon.

Scale indicators13 records

Recent moves6 records

Expansion highlights7 records

Brains Bioceutical competitors and assessment

Company assessment

Direct peers

  • MediPharm Labs: Canadian GMP-certified cannabinoid API manufacturer competing for similar pharmaceutical and nutraceutical customers. Most direct competitor in the cannabinoid API supply business, though MediPharm's regulatory certifications and scale are narrower than Brains' EU-GMP footprint.
  • Jazz Pharmaceuticals (GW Pharmaceuticals): Owns GW Pharmaceuticals, the pioneer of pharmaceutical-grade cannabinoid drug development (Epidiolex). Most direct comparison point for Brains' strategy of converting naturally-sourced cannabinoids into approved, regulated pharmaceutical products — though Jazz operates further downstream in branded drug commercialization.

Broad incumbents

  • Cronos Group: Canadian cannabis operator with pharmaceutical ambitions; Cronos Australia (a Cronos-NewSouthern JV) is an actual Brains Bio distribution partner. Competes with Brains on certain API/finished product lines and is a relevant comparable for global cannabis-pharma strategy.
  • Aurora Cannabis: Large Canadian cannabis producer with EU-GMP facilities supplying medical and consumer markets in Europe. Comparable scale of operations and regulatory positioning, though Aurora's product mix is broader and more cultivation-centric than Brains' pure API manufacturer model.
  • Canopy Growth Corporation: Major Canadian cannabis operator pursuing pharmaceutical-grade cannabinoid products and global distribution. Broader and more consumer-facing than Brains but overlaps on pharmaceutical-grade CBD positioning and clinical research investments.
  • Tilray Brands: Large diversified cannabis operator with pharmaceutical division (Tilray Medical) distributing cannabinoid APIs and finished products globally. Competes with Brains on the nutraceutical/consumer side and overlaps on API supply to pharma, but Tilray's vertically integrated cultivation-and-retail model differs from Brains' pure-play API focus.

Emerging players

  • Acreo Health Sciences: EU-based pharmaceutical-grade medical cannabis producer serving wholesalers, pharmacies, and pharma customers across Europe. Comparable in focusing on EU-GMP pharmaceutical-grade supply, though smaller scale than Brains' 12.6-ton annual capacity.
  • Botanix Pharmaceuticals: Clinical-stage cannabinoid therapeutics developer focused on dermatology and antimicrobial applications. Similar pharmaceutical-outlook strategy to Brains' pharma division but narrower indication focus and earlier pipeline stage.
  • InnoCan Pharma: Israeli-Canadian pharmaceutical company developing cannabinoid-loaded exosome and liposome delivery platforms. Connected to Brains via a Tamar Technologies distribution LOI; comparable in pharmaceutical-grade cannabinoid development though at earlier commercialization stage.
  • Cardiol Therapeutics: Clinical-stage pharmaceutical company developing cannabinoid-based therapies for inflammatory heart disease. Comparable in pursuing FDA-style regulated pathways with pharmaceutical-grade CBD formulations, though a single-indication focus rather than platform play.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Brains Bioceutical social profiles

Digital presence

Brains Bioceutical compliance and trust

Trust signal

Compliance21 records

Brains Bioceutical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Brains Bioceutical leadership team

Management profile

Number of profiles

Profiles7 records

Brains Bioceutical subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Brains Bioceutical funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Brains Bioceutical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brains Bioceutical

What does Brains Bioceutical do?

Brains Bioceutical is a cannabinoid life sciences company that manufactures EU-GMP certified pharmaceutical-grade active pharmaceutical ingredients (APIs) including CBD, D9-THC, D8-THC, CBN, and CBG at its UK facility. The company leverages these APIs across four pillars: pharmaceutical APIs for drug developers, therapeutic development programs, branded nutraceutical products, and veterinary applications. Revenue is anchored by multi-year B2B supply contracts with pharmaceutical, nutraceutical, and animal health companies globally.

Is Brains Bioceutical a public or private company?

Brains Bioceutical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Brains Bioceutical founded?

Brains Bioceutical was founded in 2015. It employs 11 to 50 people.

Where is Brains Bioceutical based?

Brains Bioceutical is headquartered in Vancouver, Canada, in the North America region.

How does Brains Bioceutical make money?

Four revenue lines are on record. Pharmaceutical API Supply is the primary driver. The others are nutraceutical Products, pharmaceutical Licensing and contract Manufacturing.

Who are Brains Bioceutical's main competitors?

Direct peers on record are MediPharm Labs and Jazz Pharmaceuticals (GW Pharmaceuticals). Broad incumbents are Cronos Group, Aurora Cannabis, Canopy Growth Corporation and Tilray Brands. Emerging players are Acreo Health Sciences, Botanix Pharmaceuticals, InnoCan Pharma and Cardiol Therapeutics.

Does Brains Bioceutical have an API?

No public API is recorded for Brains Bioceutical.

What industry is Brains Bioceutical in?

Brains Bioceutical's product category is Pharmaceutical Cannabinoid APIs. Its primary akta.pro industry code is HLAGAGAL, GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification), with a secondary code of HLAGAGAE, Process Development & Tech Transfer (Upstream/Downstream/MSAT). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyArmada to combine with Brains Bioceutical in $750m dealArmada Acquisition agreed to combine with Brains Bioceutical in a deal valuing the latter at about $750m pre-money. The combined entity, Brains Therapeutics, will list on Nasdaq under BAPI, with completion expected in Q2 2027. The transaction is subject to regulatory clearances and shareholder votes.Startup ResearcherArmada III and Brains Bioceutical Announce Business CombinationArmada Acquisition Corp. III and Brains Bioceutical Corp. announced a definitive business combination, valuing Brains at approximately US$750 million pre-money. The combined company will list on Nasdaq under BAPI, with existing Brains shareholders rolling 100% of their equity into the deal. The transaction is expected to close in the second quarter of 2027.Dealroom.coBrains to go public via SPAC merger at $750M valuationArmada Acquisition Corp. III agreed to merge with Brains Bioceutical, valuing the cannabinoid-focused firm at roughly $750 million pre-money. The combined entity, Brains Therapeutics, will trade on Nasdaq under BAPI, with closing expected in Q2 2027 subject to approvals. No PIPE funding was committed.Investing.comBrains Bioceutical to go public via SPAC at $750M valuationArmada Acquisition Corp. III and Brains Bioceutical announced a definitive business combination agreement valuing Brains at approximately $750 million. The combined company, to trade as Brains Therapeutics Corp. on Nasdaq, is expected to close in the second quarter of 2027. Brains operates a cannabinoid API manufacturing facility and holds an option to license an NIH-funded opioid use disorder program.Business Wire BlogArmada Acquisition Corp. III and Brains Bioceutical Corp. Announce Business Combination to Advance a Global Life Sciences and Pharmaceutical Innovation PlatformArmada Acquisition Corp. III and Brains Bioceutical announced a definitive business combination to form Brains Therapeutics Corp., to be listed on Nasdaq under 'BAPI'. Brains is valued at an implied pre-money equity value of approximately $750 million, with the transaction expected to close in the second quarter of 2027.Stock TitanArmada III, Brains agree on about $750M pre-money valuationArmada Acquisition Corp. III and Brains Bioceutical announced a definitive business combination agreement, valuing Brains at an implied pre-money equity value of approximately $750 million. The combined company, expected to trade on Nasdaq under 'BAPI', is anticipated to close in the second quarter of 2027.BenzingaEXCLUSIVE: LATAM Pharma Giant Signs Landmark Supply Deal With World's Top Cannabinoid ProducerBrains Bioceutical Corporation, the world's largest manufacturer of natural cannabinoid active pharmaceutical ingredients, has signed a landmark supply agreement with Prati-Donaduzzi, one of the largest drug manufacturers in South America, to supply natural EU-GMP CBD API for clinical trials and products approved by Brazil's Health Regulatory Agency. The agreement represents one of the world's most extensive pharmaceutical cannabinoid supply agreements to date, with Prati-Donaduzzi sourcing Brains Bio's premium CBD API for ongoing trials and cannabinoid-based medicines. Both companies expect the partnership to culminate in market-authorized prescription medicines, as the global market for cannabinoid-based drugs is projected to reach $56 billion by 2026.PR NewswireCannabidiol (CBD) API Market to Record Rapid Growth with CAGR of 41.7% by 2030 - Exclusive Report by InsightAce AnalyticInsightAce Analytic Pvt. Ltd. published a market research report predicting the global Cannabidiol (CBD) API market will grow at a CAGR of 41.7% between 2022 and 2030, driven by increasing demand for health and wellness products, regulatory approvals, and expanding therapeutic applications. The report identifies key growth drivers including government funding for therapeutic research, partnerships between major market players, and rising patient adoption, while noting that FDA cautiousness on CBD approvals and high product prices remain significant challenges. Notable recent developments include 22nd Century Group's acquisition of GVB Biopharma in May 2022, Averix Bio's Drug Master File submission to the FDA, and DSM's exclusive global cooperation with Brains Bioceutical for cannabinoid-based pharmaceutical development.PR NewswireBRAINS BIOCEUTICAL'S NATURAL, PLANT-BASED CANNABIDIOL RECEIVES NOVEL FOOD VALIDATION FROM THE UNITED KINGDOM FOOD STANDARDS AGENCYBrains Bioceutical Corp., through its subsidiary BSPG Laboratories Ltd., has received novel food validation from the UK Food Standards Agency for its natural, plant-based CBD active pharmaceutical ingredient, making it the first company to achieve this status among over 800 applications with only three fully validated and over 600 rejected. This first-mover advantage positions Brains Bio as the only manufacturer able to meet demand for natural plant-based CBD products in the UK and European markets, where such validation is required for any CBD nutraceutical products. The company had previously received European Novel Foods validation from the European Commission and European Food Safety Authority earlier in 2022.